Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belantamab mafodotin + bortezomib + dexamethasone in relapsed/refractory multiple myeloma
2024-516250-22-00Phase 2Authorised
- Sponsor
- Czech Myeloma Group
- Start
- Apr 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of belantamab mafodotin, bortezomib and dexamethasone in multiple myeloma (MM), sponsored by Czech Myeloma Group. Primary endpoints: Overall response rate and Incidence of grade 3 or higher ocular adverse events. Planned start Apr 2023; status: authorised.
02
Drugs
belantamab mafodotinbortezomibdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2024-516250-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516250-22-00.